So basically being cheap is only way to make money. Selling diet pills? Reminds me of Wall-E.
@jjchen20376 ай бұрын
Than you very much!
@user-uc3zp8dl3f6 ай бұрын
A comprehensive review of the bio innovation landscape! Thank you
@annakuta80318 ай бұрын
it looks like the government destroys the market again
@BK46ers8 ай бұрын
Thank you, Bruce!
@sebastianaguiarbrunemeier91928 ай бұрын
Nice job as always Bruce! Rock on
@cliffmiras86858 ай бұрын
Outstanding succinct review. Thank you for sharing.
@rajivtyagi51428 ай бұрын
Bruce evey year I wait for your review. This is the best review of our industry. God bless you
@davidlarose88088 ай бұрын
Any slides pdf?
@user-nd7jx7xn5h8 ай бұрын
Year after year, Bruce and team create and share what consistently feels like the best biopharma review in the business - always so great to see this consolidated perspective.
@alexeykadet Жыл бұрын
Highly enjoyed the overview. Thank you! I'd like connect with you sometime.
@bz9999 Жыл бұрын
This is a great overview of the year in biotech venture generally, and Atlas specifically.
@sebastianaguiarbrunemeier9192 Жыл бұрын
Nice overview Bruce! As always very insightful. I wouldn't celebrate the amyloid targeting drugs, it's going to harm the entire AD pipeline -- by doubling down on amyloid at the expense of fresh new approaches.
@gjs2900 Жыл бұрын
great presentation Bruce
@AaS-mb6ct2 жыл бұрын
Fanning the flames of convid
@sebastianaguiarbrunemeier91922 жыл бұрын
Very compelling as usual. Keep up the great analysis, Bruce and team!
@samshrivastava26552 жыл бұрын
Bruce. Always doing a great recap and state of the (union) of the biotech community. Kudos.
@sebastianaguiarbrunemeier91924 жыл бұрын
Another great presentation Bruce. I also lament the underwhelming rate of progress, especially in age-related diseases like cancer (3% gain in 5-year survival after 20 years of research and hundreds of billions spent -- hopefully 'new' paradigms I/O will steepen the slope). Most biopharma resources go into oncology and yet we can barely move the needle for solid tumors -- maybe we need fresh ideas. The major risk factor for cancer, CVD, and dementia is biological age. So what if we could target the molecular damage that causes aging, and thereby all of these diseases? We can already extend healthy lifespan in mice by up to 30% with no negative side effects -- for example, by senescent cell ablation, autophagy enhancement, and various types of gene and cell therapy that address the primary, causal 'Hallmarks of Aging.' This 'geroscience' approach is led by groups like Apollo Ventures and Cambrian Biopharma (in stealth mode, stay tuned) -- target the biology of aging and develop a 'pipeline-in-a-pill' for multiple age-related diseases and, one day, as a prophylactic against aging itself. Keep up the great work. "From discoveries in ageing research to therapeutics for healthy ageing" www.nature.com/articles/s41586-019-1365-2 "The Hallmarks of Aging" www.cell.com/fulltext/S0092-8674(13)00645-4
@Geroscientist4 жыл бұрын
Completely agreed. Anyone in biotech who isn't watching the aging space has no understanding of pathophysiology of age-related disease - i.e. as related to the Hallmarks of Aging. Even last week seeing that BS about CRISPR having a chance at 'curing' CVD by targeting cholesterol is revealing. Imagine thinking cholesterol matters in heart disease when it is a mere 3x risk factor as compared to aging, a 5000x risk factor: imgur.com/gallery/i2mYKze The aging biology field WILL revolutionise medicine; at least inform yourself if you don't know what I'm talking about; the number of papers published in CNS journals on aging in the last decade has exploded and the geroscience hypothesis will see its light of day.
Пікірлер
So basically being cheap is only way to make money. Selling diet pills? Reminds me of Wall-E.
Than you very much!
A comprehensive review of the bio innovation landscape! Thank you
it looks like the government destroys the market again
Thank you, Bruce!
Nice job as always Bruce! Rock on
Outstanding succinct review. Thank you for sharing.
Bruce evey year I wait for your review. This is the best review of our industry. God bless you
Any slides pdf?
Year after year, Bruce and team create and share what consistently feels like the best biopharma review in the business - always so great to see this consolidated perspective.
Highly enjoyed the overview. Thank you! I'd like connect with you sometime.
This is a great overview of the year in biotech venture generally, and Atlas specifically.
Nice overview Bruce! As always very insightful. I wouldn't celebrate the amyloid targeting drugs, it's going to harm the entire AD pipeline -- by doubling down on amyloid at the expense of fresh new approaches.
great presentation Bruce
Fanning the flames of convid
Very compelling as usual. Keep up the great analysis, Bruce and team!
Bruce. Always doing a great recap and state of the (union) of the biotech community. Kudos.
Another great presentation Bruce. I also lament the underwhelming rate of progress, especially in age-related diseases like cancer (3% gain in 5-year survival after 20 years of research and hundreds of billions spent -- hopefully 'new' paradigms I/O will steepen the slope). Most biopharma resources go into oncology and yet we can barely move the needle for solid tumors -- maybe we need fresh ideas. The major risk factor for cancer, CVD, and dementia is biological age. So what if we could target the molecular damage that causes aging, and thereby all of these diseases? We can already extend healthy lifespan in mice by up to 30% with no negative side effects -- for example, by senescent cell ablation, autophagy enhancement, and various types of gene and cell therapy that address the primary, causal 'Hallmarks of Aging.' This 'geroscience' approach is led by groups like Apollo Ventures and Cambrian Biopharma (in stealth mode, stay tuned) -- target the biology of aging and develop a 'pipeline-in-a-pill' for multiple age-related diseases and, one day, as a prophylactic against aging itself. Keep up the great work. "From discoveries in ageing research to therapeutics for healthy ageing" www.nature.com/articles/s41586-019-1365-2 "The Hallmarks of Aging" www.cell.com/fulltext/S0092-8674(13)00645-4
Completely agreed. Anyone in biotech who isn't watching the aging space has no understanding of pathophysiology of age-related disease - i.e. as related to the Hallmarks of Aging. Even last week seeing that BS about CRISPR having a chance at 'curing' CVD by targeting cholesterol is revealing. Imagine thinking cholesterol matters in heart disease when it is a mere 3x risk factor as compared to aging, a 5000x risk factor: imgur.com/gallery/i2mYKze The aging biology field WILL revolutionise medicine; at least inform yourself if you don't know what I'm talking about; the number of papers published in CNS journals on aging in the last decade has exploded and the geroscience hypothesis will see its light of day.
Great overview, many thanks Bruce
Very nice design